Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines外文翻译.PDFVIP

Preclinical report 1 Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines a a c a Rebekka Unland , Dagmar Clemens , Ulrike Heinicke , Jenny C. Potratz , a c b a,d Marc Hotfilder , Simone Fulda , Eva Wardelmann , Michael C. Frühwald and Uta Dirksena Ewing sarcomas (ES) are highly malignant tumors arising in analyses, pretreatment with SAHA significantly increased bone and soft tissues. Given the poor outcome of affected the effects of etoposide on apoptosis and clonogenicity. The patients with primary disseminated disease or at relapse, in-vitro analyses presented in this work show that SAHA there is a clear need for new targeted therapies. The HDAC synergistically enhances the antitumor activity of etoposide inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA, in ES cells. Sequential treatment with etoposide combined Vorinostat) inhibits ES tumor growth and induces apoptosis with SAHA may represent a new therapeutic approach in in vitro and in vivo. Thus, SAHA may be considered a novel ES. Anti-Cancer Drugs 00:000–000 Copyright © 2015 treatment. However, it is most likely that not a single agent Wolters Kluwer Health, Inc. All rights reserved. but a combination of agents with synergistic mechanisms Anti-Cancer Drugs 2015, 00:000–000 will help improve the prognosis in high-risk ES patien